x
CME-Tagline

Addressing Disparities in Care: Assessing Patient Characteristics When Determining Next Steps for Anticoagulant Treatment Selection

CMEO BriefCase

Premiere Date: Friday, July 9, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. ABIM (MOC)
  4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Saturday, July 9, 2022

Faculty


Gregory Piazza, MD, MS Gregory Piazza, MD, MS (Moderator)
Director, Vascular Medicine Section
Brigham and Women's Hospital
Associate Professor of Medicine
Cardiovascular Medicine
Harvard Medical School
Boston, MA

Karol E. Watson, MD, PhD, FACC, FAHA Karol E. Watson, MD, PhD, FACC, FAHA 
Professor of Medicine/Cardiology
Co-Director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women's Heart Health Program
John Mazziotta, MD, PhD, Term Chair in Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Statement of Need

Venous thromboembolism (VTE) incidence varies by race/ethnicity, with Black people being at the greatest risk, followed by White, Hispanic, and Asian people. Studies suggest that provider interactions with patients of color are less patient-centered, with fewer requestsfor patient input about VTE treatment decisions. Therefore race/ethnicity and socioeconomics were found to influence direct oral anticoagulant (DOAC) uptake, and efforts to improve equitable medication uptake and utilization among all racial, ethnic, and socioeconomic groups is needed.

The second installment of this CME Outfitters BriefCase series introduces Gordon, a 67-year-old Black man who complains of recent pain and swelling in his right leg, and explores this case with a focus on the impact of racial and ethnic disparities on the care of individuals who are candidates for anticoagulation therapy, and applying patient selection criteria for anticoagulation treatment that minimizes disparities and unconscious bias to optimize patient outcomes.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the impact of racial and ethnic disparities on the care of individuals who are candidates for anticoagulation therapy.
  • Apply patient selection criteria for anticoagulation treatment that minimizes disparities and unconscious bias to optimize outcomes.

The following learning objectives pertain only to those requesting CNE credit:

  • Recognize the impact of racial and ethnic disparities on the care of individuals who are candidates for anticoagulation therapy.
  • Identify patient selection criteria for anticoagulation treatment that minimizes disparities and unconscious bias to optimize outcomes.

Financial Support

Supported by educational grants from the Bristol Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. administered by Janssen Scientific Affairs, LLC.

Target Audience

VTE specialists, pulmonologists, hematologist-oncologists, emergency physicians, internists, family practitioners, PAs, nurse practitioners, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.75 contact hours (0.075 CEUs) Universal Activity Number:
Enduring: 0376-0000-21-172-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Format
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note to PAs: PAs may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Piazza reports that he receives grants from Amgen Inc.; Bayer; Bristol-Myers Squibb and Pfizer Alliance; Boston Scientific Corporation; Janssen Pharmaceuticals, Inc.; and Portola Pharmaceuticals, Inc.

Dr. Watson reports that she is on the speakers bureau for Boehringer Ingelheim and Eli Lilly and Company. She is a consultant for Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Eli Lilly and Company; and Esperion Therapeutics.

Michael J. Franks, MSN, AGACNP-BC, FNP, BC (peer reviewer) has no disclosures to report.

Warren Beckman (planning committee) has no disclosures to report.

Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

BC-047-070921-90